Browsing Research publications by Subject "PHASE-3"
Now showing items 1-1 of 1
-
(JCO Precision Oncology, 2019-06-27)PURPOSE To study whether BRAF V600 mutations in non-small-cell lung cancer (NSCLC) may indicate sensitivity to the BRAF inhibitor vemurafenib, we included a cohort of patients with NSCLC in the vemurafenib basket (VE-BASKET) ...